Decitabine

Decitabine
Clinical data
Trade names	Dacogen, Demylocan
Other names	5-aza-2'-deoxycytidine
AHFS/Drugs.com	Monograph
MedlinePlus	a608009
License data	US DailyMed: Decitabine;
Routes of; administration	Intravenous
ATC code	L01BC08 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	<1%
Elimination half-life	30 minutes
Identifiers
	IUPAC name 4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one;
CAS Number	2353-33-5 ;
PubChem CID	451668;
IUPHAR/BPS	6805;
DrugBank	DB01262 ;
ChemSpider	397844 ;
UNII	776B62CQ27;
KEGG	D03665 ;
ChEBI	CHEBI:50131 ;
ChEMBL	ChEMBL1201129 ;
CompTox Dashboard (EPA)	DTXSID7030432 ;
ECHA InfoCard	100.017.355
Chemical and physical data
Formula	C8H12N4O4
Molar mass	228.208 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1/N=C(\N=C/N1[C@@H]2O[C@@H]([C@@H](O)C2)CO)N;
	InChI InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1 ; Key:XAUDJQYHKZQPEU-KVQBGUIXSA-N ;
	(what is this?) (verify)

Decitabine (i.e., 5-aza-2′-deoxycytidine), sold under the brand name Dacogen among others, acts as a nucleic acid synthesis inhibitor.^[4] It is a medication for the treatment of myelodysplastic syndromes, a class of conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia (AML).^[5] Chemically, it is a cytidine analog.

^ "Summary Basis of Decision (SBD) for Dacogen". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ "Summary Basis of Decision (SBD) for Demylocan". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ "Dacogen EPAR". European Medicines Agency (EMA). 8 June 2006. Retrieved 4 June 2024.
^ "Decitabine". National Center for Biotechnology Information. Retrieved September 24, 2016.
^ "EC Approves Marketing Authorization Of DACOGEN For Acute Myeloid Leukemia". 2012-09-28. Retrieved 28 September 2012.

[1] "Summary Basis of Decision (SBD) for Dacogen". Health Canada. 23 October 2014. Retrieved 29 May 2022.

[2] "Summary Basis of Decision (SBD) for Demylocan". Health Canada. 23 October 2014. Retrieved 29 May 2022.

[3] "Dacogen EPAR". European Medicines Agency (EMA). 8 June 2006. Retrieved 4 June 2024.

[4] "Decitabine". National Center for Biotechnology Information. Retrieved September 24, 2016.

[EC-AML-5] "EC Approves Marketing Authorization Of DACOGEN For Acute Myeloid Leukemia". 2012-09-28. Retrieved 28 September 2012.

[1]

[2]

[3]

[4]

[5]